Sycomore Asset Management Purchases 5,746 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sycomore Asset Management raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 63.0% in the third quarter, HoldingsChannel reports. The firm owned 14,866 shares of the medical equipment provider’s stock after buying an additional 5,746 shares during the quarter. Sycomore Asset Management’s holdings in Intuitive Surgical were worth $7,230,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Mirador Capital Partners LP grew its stake in shares of Intuitive Surgical by 1.4% during the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after acquiring an additional 50 shares during the period. Advisors Asset Management Inc. lifted its holdings in Intuitive Surgical by 18.1% in the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after purchasing an additional 1,129 shares in the last quarter. Consolidated Planning Corp lifted its holdings in Intuitive Surgical by 17.4% in the 3rd quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider’s stock worth $3,979,000 after purchasing an additional 1,198 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Intuitive Surgical by 617.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after purchasing an additional 76,649 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in Intuitive Surgical by 22.4% in the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock worth $5,340,000 after purchasing an additional 2,289 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price target on Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a report on Friday, October 18th. BTIG Research set a $535.00 price objective on Intuitive Surgical in a report on Friday, October 18th. Mizuho upped their price objective on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. upped their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $513.74.

Insider Buying and Selling

In other news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the transaction, the director now owns 821 shares of the company’s stock, valued at $402,519.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the transaction, the director now owns 821 shares in the company, valued at approximately $402,519.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 91,178 shares of company stock worth $45,897,071. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Price Performance

ISRG stock traded up $6.84 during trading on Thursday, hitting $543.53. 397,463 shares of the company traded hands, compared to its average volume of 1,454,509. The company has a market cap of $193.59 billion, a PE ratio of 86.28, a P/E/G ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $291.39 and a 1 year high of $544.38. The stock’s 50-day simple moving average is $496.95 and its 200 day simple moving average is $455.65.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Research analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.